Soluble Ig-like transcript 3 inhibits tumor allograft rejection in humanized SCID mice and T cell responses in cancer patients

Nicole Suciu-Foca, Nikki Feirt, Qing Yin Zhang, George Vlad, Zhuoru Liu, Hana Lin, Chili Chao Chang, Eric K. Ho, Adriana I. Colovai, Howard Kaufman, Vivette D. D'Agati, Harshwardhan Thaker, Helen Remotti, Sara Galluzzo, Paola Cinti, Carla Rabitti, John Allendorf, John Chabot, Marco Caricato, Roberto Coppola & 2 others Pasquale Berloco, Raffaello Cortesini

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Attempts to enhance patients' immune responses to malignancies have been largely unsuccessful. We now describe an immune-escape mechanism mediated by the inhibitory receptor Ig-like transcript 3 (ILT3) that may be responsible for such failures. Using a humanized SCID mouse model, we demonstrate that soluble and membrane ILT3 induce CD8+ T suppressor cells and prevent rejection of allogeneic tumor transplants. Furthermore, we found that patients with melanoma, and carcinomas of the colon, rectum, and pancreas produce the soluble ILT3 protein, which induces the differentiation of CD8+ T suppressor cells and impairs T cell responses in MLC. These responses are restored by anti-ILT3 mAb or by depletion of soluble ILT3 from the serum. Immunohistochemical staining of biopsies from the tumors and metastatic lymph nodes suggests that CD68+ tumor-associated macrophages represent the major source of soluble ILT3. Alternative splicing, resulting in the loss of the ILT3 transmembrane domain, may contribute to the release of ILT3 in the circulation. These data suggest that ILT3 depletion or blockade is crucial to the success of immunotherapy in cancer. In contrast, the inhibitory activity of soluble ILT3 on T cell alloreactivity in vitro and in vivo suggests the potential usefulness of rILT3 for immunosuppressive treatment of allograft recipients or patients with autoimmune diseases.

Original languageEnglish (US)
Pages (from-to)7432-7441
Number of pages10
JournalJournal of Immunology
Volume178
Issue number11
DOIs
StatePublished - Jun 1 2007
Externally publishedYes

Fingerprint

SCID Mice
Allografts
T-Lymphocytes
Neoplasms
Alternative Splicing
Immunosuppressive Agents
Rectum
Immunotherapy
Autoimmune Diseases
Pancreas
Melanoma
Colon
Lymph Nodes
Macrophages
Staining and Labeling
Carcinoma
Transplants
Biopsy
Membranes
Serum

ASJC Scopus subject areas

  • Immunology

Cite this

Soluble Ig-like transcript 3 inhibits tumor allograft rejection in humanized SCID mice and T cell responses in cancer patients. / Suciu-Foca, Nicole; Feirt, Nikki; Zhang, Qing Yin; Vlad, George; Liu, Zhuoru; Lin, Hana; Chang, Chili Chao; Ho, Eric K.; Colovai, Adriana I.; Kaufman, Howard; D'Agati, Vivette D.; Thaker, Harshwardhan; Remotti, Helen; Galluzzo, Sara; Cinti, Paola; Rabitti, Carla; Allendorf, John; Chabot, John; Caricato, Marco; Coppola, Roberto; Berloco, Pasquale; Cortesini, Raffaello.

In: Journal of Immunology, Vol. 178, No. 11, 01.06.2007, p. 7432-7441.

Research output: Contribution to journalArticle

Suciu-Foca, N, Feirt, N, Zhang, QY, Vlad, G, Liu, Z, Lin, H, Chang, CC, Ho, EK, Colovai, AI, Kaufman, H, D'Agati, VD, Thaker, H, Remotti, H, Galluzzo, S, Cinti, P, Rabitti, C, Allendorf, J, Chabot, J, Caricato, M, Coppola, R, Berloco, P & Cortesini, R 2007, 'Soluble Ig-like transcript 3 inhibits tumor allograft rejection in humanized SCID mice and T cell responses in cancer patients', Journal of Immunology, vol. 178, no. 11, pp. 7432-7441. https://doi.org/10.4049/jimmunol.178.11.7432
Suciu-Foca, Nicole ; Feirt, Nikki ; Zhang, Qing Yin ; Vlad, George ; Liu, Zhuoru ; Lin, Hana ; Chang, Chili Chao ; Ho, Eric K. ; Colovai, Adriana I. ; Kaufman, Howard ; D'Agati, Vivette D. ; Thaker, Harshwardhan ; Remotti, Helen ; Galluzzo, Sara ; Cinti, Paola ; Rabitti, Carla ; Allendorf, John ; Chabot, John ; Caricato, Marco ; Coppola, Roberto ; Berloco, Pasquale ; Cortesini, Raffaello. / Soluble Ig-like transcript 3 inhibits tumor allograft rejection in humanized SCID mice and T cell responses in cancer patients. In: Journal of Immunology. 2007 ; Vol. 178, No. 11. pp. 7432-7441.
@article{8b22aa6dd21e4ba09991c4c7550fef39,
title = "Soluble Ig-like transcript 3 inhibits tumor allograft rejection in humanized SCID mice and T cell responses in cancer patients",
abstract = "Attempts to enhance patients' immune responses to malignancies have been largely unsuccessful. We now describe an immune-escape mechanism mediated by the inhibitory receptor Ig-like transcript 3 (ILT3) that may be responsible for such failures. Using a humanized SCID mouse model, we demonstrate that soluble and membrane ILT3 induce CD8+ T suppressor cells and prevent rejection of allogeneic tumor transplants. Furthermore, we found that patients with melanoma, and carcinomas of the colon, rectum, and pancreas produce the soluble ILT3 protein, which induces the differentiation of CD8+ T suppressor cells and impairs T cell responses in MLC. These responses are restored by anti-ILT3 mAb or by depletion of soluble ILT3 from the serum. Immunohistochemical staining of biopsies from the tumors and metastatic lymph nodes suggests that CD68+ tumor-associated macrophages represent the major source of soluble ILT3. Alternative splicing, resulting in the loss of the ILT3 transmembrane domain, may contribute to the release of ILT3 in the circulation. These data suggest that ILT3 depletion or blockade is crucial to the success of immunotherapy in cancer. In contrast, the inhibitory activity of soluble ILT3 on T cell alloreactivity in vitro and in vivo suggests the potential usefulness of rILT3 for immunosuppressive treatment of allograft recipients or patients with autoimmune diseases.",
author = "Nicole Suciu-Foca and Nikki Feirt and Zhang, {Qing Yin} and George Vlad and Zhuoru Liu and Hana Lin and Chang, {Chili Chao} and Ho, {Eric K.} and Colovai, {Adriana I.} and Howard Kaufman and D'Agati, {Vivette D.} and Harshwardhan Thaker and Helen Remotti and Sara Galluzzo and Paola Cinti and Carla Rabitti and John Allendorf and John Chabot and Marco Caricato and Roberto Coppola and Pasquale Berloco and Raffaello Cortesini",
year = "2007",
month = "6",
day = "1",
doi = "10.4049/jimmunol.178.11.7432",
language = "English (US)",
volume = "178",
pages = "7432--7441",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "11",

}

TY - JOUR

T1 - Soluble Ig-like transcript 3 inhibits tumor allograft rejection in humanized SCID mice and T cell responses in cancer patients

AU - Suciu-Foca, Nicole

AU - Feirt, Nikki

AU - Zhang, Qing Yin

AU - Vlad, George

AU - Liu, Zhuoru

AU - Lin, Hana

AU - Chang, Chili Chao

AU - Ho, Eric K.

AU - Colovai, Adriana I.

AU - Kaufman, Howard

AU - D'Agati, Vivette D.

AU - Thaker, Harshwardhan

AU - Remotti, Helen

AU - Galluzzo, Sara

AU - Cinti, Paola

AU - Rabitti, Carla

AU - Allendorf, John

AU - Chabot, John

AU - Caricato, Marco

AU - Coppola, Roberto

AU - Berloco, Pasquale

AU - Cortesini, Raffaello

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Attempts to enhance patients' immune responses to malignancies have been largely unsuccessful. We now describe an immune-escape mechanism mediated by the inhibitory receptor Ig-like transcript 3 (ILT3) that may be responsible for such failures. Using a humanized SCID mouse model, we demonstrate that soluble and membrane ILT3 induce CD8+ T suppressor cells and prevent rejection of allogeneic tumor transplants. Furthermore, we found that patients with melanoma, and carcinomas of the colon, rectum, and pancreas produce the soluble ILT3 protein, which induces the differentiation of CD8+ T suppressor cells and impairs T cell responses in MLC. These responses are restored by anti-ILT3 mAb or by depletion of soluble ILT3 from the serum. Immunohistochemical staining of biopsies from the tumors and metastatic lymph nodes suggests that CD68+ tumor-associated macrophages represent the major source of soluble ILT3. Alternative splicing, resulting in the loss of the ILT3 transmembrane domain, may contribute to the release of ILT3 in the circulation. These data suggest that ILT3 depletion or blockade is crucial to the success of immunotherapy in cancer. In contrast, the inhibitory activity of soluble ILT3 on T cell alloreactivity in vitro and in vivo suggests the potential usefulness of rILT3 for immunosuppressive treatment of allograft recipients or patients with autoimmune diseases.

AB - Attempts to enhance patients' immune responses to malignancies have been largely unsuccessful. We now describe an immune-escape mechanism mediated by the inhibitory receptor Ig-like transcript 3 (ILT3) that may be responsible for such failures. Using a humanized SCID mouse model, we demonstrate that soluble and membrane ILT3 induce CD8+ T suppressor cells and prevent rejection of allogeneic tumor transplants. Furthermore, we found that patients with melanoma, and carcinomas of the colon, rectum, and pancreas produce the soluble ILT3 protein, which induces the differentiation of CD8+ T suppressor cells and impairs T cell responses in MLC. These responses are restored by anti-ILT3 mAb or by depletion of soluble ILT3 from the serum. Immunohistochemical staining of biopsies from the tumors and metastatic lymph nodes suggests that CD68+ tumor-associated macrophages represent the major source of soluble ILT3. Alternative splicing, resulting in the loss of the ILT3 transmembrane domain, may contribute to the release of ILT3 in the circulation. These data suggest that ILT3 depletion or blockade is crucial to the success of immunotherapy in cancer. In contrast, the inhibitory activity of soluble ILT3 on T cell alloreactivity in vitro and in vivo suggests the potential usefulness of rILT3 for immunosuppressive treatment of allograft recipients or patients with autoimmune diseases.

UR - http://www.scopus.com/inward/record.url?scp=34249788694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249788694&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.178.11.7432

DO - 10.4049/jimmunol.178.11.7432

M3 - Article

VL - 178

SP - 7432

EP - 7441

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 11

ER -